Ozempic vs Zepbound: Two different molecules, compared

Ozempic and Zepbound get compared constantly, usually by people trying to decide which one to ask about for weight loss. The comparison is harder than it looks, because these two products differ in two ways at once. They contain different molecules, and they are approved for different things.

This article separates those two differences, covers what the trial data shows, and explains why the labeling distinction affects almost everything practical. It is educational and not medical advice.

Two differences, not one

Ozempic contains semaglutide and is approved for type 2 diabetes. Its labeled uses are improving blood sugar control in adults with type 2 diabetes and reducing cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. Weight management is not on its label. Semaglutide at higher doses is approved for weight management, but under a different brand name and as a separate product.

Zepbound contains tirzepatide and is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It also carries an approval for moderate to severe obstructive sleep apnea in adults with obesity. Tirzepatide is approved for type 2 diabetes too, again under a different brand name.

So a fair reading is that these are not two options for the same job. One is a diabetes medication that causes weight loss as an effect. The other is a weight management medication.

How the molecules differ

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone the gut releases after eating, acting on brain receptors that regulate appetite and fullness, and slowing gastric emptying.

Tirzepatide acts on two receptors, GLP-1 and GIP. GIP is a second incretin hormone, and combining the two activities is the design premise of the molecule. Brain expression of GIP receptors does not fully overlap with GLP-1 receptors, and researchers have proposed that this contributes to the effects observed with dual agonism.

Both are once-weekly subcutaneous injections.

Off-label prescribing, honestly

Ozempic is sometimes prescribed off-label for weight management. Off-label prescribing is legal and routine across medicine. A provider may prescribe an approved drug for an unapproved use when they judge it clinically appropriate.

What that does not mean: it does not mean the manufacturer may promote it that way, it does not mean insurance will cover it that way, and it is not something you can arrange around a provider. It is their clinical judgment, exercised for you specifically.

In practice, coverage is where this bites. A plan that covers Ozempic for diabetes will usually not cover it for weight management.

What the comparison data shows

There is no head-to-head trial of these two brands, because they are approved for different indications and studied at different doses. What exists is a head-to-head trial of the two molecules at diabetes doses.

SURPASS-2 was a 40-week open-label trial of 1,879 adults with type 2 diabetes taking metformin, randomized to tirzepatide at 5, 10, or 15 mg or to semaglutide 1 mg, the highest semaglutide dose then approved for diabetes [1].

A1C reductions were 2.09%, 2.37%, and 2.46% across the tirzepatide doses, against 1.86% for semaglutide [1]. Body weight reductions were 7.8 kg, 10.3 kg, and 12.4 kg respectively, against 6.2 kg for semaglutide [1]. The investigators reported tirzepatide as superior on both measures [1]. Gastrointestinal events were the most common adverse events across all arms, generally mild to moderate [1].

Read that carefully before extrapolating. This trial compared diabetes doses in people with diabetes. Zepbound is prescribed at weight management doses in people who mostly do not have diabetes. The trial tells you something real about the two molecules, and it does not tell you what either brand will do for you.

A separate head-to-head trial compared the two molecules at their weight management doses, in adults with obesity and without diabetes, and is covered in our Wegovy and Zepbound comparison.

Both of these are prescription medications with meaningful risks. Both carry a boxed warning for thyroid C-cell tumors based on rodent studies, with a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both share the class considerations: gastrointestinal effects, pancreatitis, gallbladder problems, dehydration that can affect the kidneys, and serious hypersensitivity reactions. A provider goes through this against your history.

Cost and insurance

The indication difference drives the cost difference more than the drugs do.

Diabetes indications are covered far more widely than weight management indications. Many employer plans cover GLP-1s for diabetes and explicitly exclude them for weight. That single fact is why some people end up paying cash for one and a copay for the other.

Prior authorization applies to both, documenting different things: glycemic control and prior therapies for the diabetes product, BMI and weight-related conditions for the weight management product.

Manufacturer savings programs exist for both, generally for people with commercial insurance and generally excluding government plans.

Direct cash-pay channels from both manufacturers have expanded.

List prices are broadly comparable. What you actually pay is not, and it depends on which indication your prescription is written under and what your plan does with it.

Compounded formulations

Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies. They are not FDA-approved, and the FDA does not evaluate compounded drugs for safety, effectiveness, or quality. No figure in this article describes them: everything above comes from trials of the approved products. Our pages on compounded semaglutide and compounded tirzepatide cover that topic, and the decision belongs with a licensed provider.

How a provider decides

The first question is not which drug. It is what is being treated.

If you have type 2 diabetes, the conversation runs through glycemic control, cardiovascular risk, your other diabetes medications, and weight as one goal among several. If you do not have diabetes and weight is the reason you are there, a medication approved for that use is the straightforward starting point, and a provider is unlikely to reach for an off-label option first without a reason.

After that: your cardiovascular history, whether you have sleep apnea, how you have tolerated medications before, what your plan will approve, and what you have already tried.

Common questions

Is Zepbound stronger than Ozempic?

They are not on a single scale, because they are dosed for different purposes. In SURPASS-2, which compared the two molecules at diabetes doses, tirzepatide produced greater A1C and weight reductions than semaglutide 1 mg [1]. That is a finding about those doses in that population. It does not translate into a ranking of the two brands as you would receive them.

Can I use Ozempic for weight loss?

It is not approved for that, and it is sometimes prescribed off-label by a provider who judges it appropriate. Insurance generally will not cover it for that purpose. If weight management is the goal, ask your provider about the products approved for it.

What is the cost difference?

List prices are broadly similar. The real difference comes from coverage, and diabetes indications are covered much more often than weight management indications. Check your own formulary rather than a published price.

Can I switch between them?

Switching happens with provider guidance. The dose numbers do not translate between two different molecules, so a provider restarts a titration rather than matching your current dose, and the escalation side effects usually return for a while.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review.

Explore Luvo's Weight Loss Program.